Trial · NCT01475825
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Regimen A: Mipomersen, 200 mg, Once Weekly | 104 | |
| Overall Study | STARTED | Regimen A: Placebo, Once Weekly | 51 | |
| Overall Study | STARTED | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 102 | |
| Overall Study | STARTED | Regimen B: Placebo, Thrice Weekly | 52 | |
| Overall Study | Randomized and Treated | Regimen A: Mipomersen, 200 mg, Once Weekly | 104 | |
| Overall Study | Randomized and Treated | Regimen A: Placebo, Once Weekly | 51 | |
| Overall Study | Randomized and Treated | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 102 | |
| Overall Study | Randomized and Treated | Regimen B: Placebo, Thrice Weekly | 52 | |
| Overall Study | Completed Blinded Treatment Period | Regimen A: Mipomersen, 200 mg, Once Weekly | 60 | |
| Overall Study | Completed Blinded Treatment Period | Regimen A: Placebo, Once Weekly | 42 | |
| Overall Study | Completed Blinded Treatment Period | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 59 | |
| Overall Study | Completed Blinded Treatment Period | Regimen B: Placebo, Thrice Weekly | 40 | |
| Overall Study | Entered Open-Label Continuation | Regimen A: Mipomersen, 200 mg, Once Weekly | 45 | |
| Overall Study | Entered Open-Label Continuation | Regimen A: Placebo, Once Weekly | 31 | |
| Overall Study | Entered Open-Label Continuation | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 44 | |
| Overall Study | Entered Open-Label Continuation | Regimen B: Placebo, Thrice Weekly | 29 | |
| Overall Study | Completed Open-Label Continuation | Regimen A: Mipomersen, 200 mg, Once Weekly | 37 | |
| Overall Study | Completed Open-Label Continuation | Regimen A: Placebo, Once Weekly | 19 | |
| Overall Study | Completed Open-Label Continuation | Regimen B: Mipomersen, 70 mg, Thrice Weekly | 38 | |
| Overall Study | Completed Open-Label Continuation | Regimen B: Placebo, Thrice Weekly | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01475825/flow